Market Research

Rheumatology Therapeutics Market (Drug Class: Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 205 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827839
Best Price Guarantee
Price from $5,795
Length 205 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827839

Rheumatology Therapeutics Market (Drug Class: Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Rheumatology Therapeutics Market – Scope of Report

TMR’s report on the global rheumatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global rheumatology therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatology therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the rheumatology therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatology therapeutics market.

The report delves into the competitive landscape of the global rheumatology therapeutics market. Key players operating in the global rheumatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatology therapeutics market profiled in this report.

Key Questions Answered in Global rheumatology therapeutics Market Report
  • What is the sales/revenue generated by rheumatology therapeutics across all regions during the forecast period?
  • What are the opportunities in the global rheumatology therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Rheumatology Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global rheumatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatology therapeutics market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Rheumatology Therapeutics Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution / Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product/Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
  6.1. Introduction and Definitions
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Drug Class, 2020-2034
  6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  6.3.3. Corticosteroids
  6.3.4. Uric Acid Drugs
  6.3.5. Others
  6.4. Market Attractiveness, by Drug Class
7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication
  7.1. Introduction and Definitions
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Disease Indication, 2020-2034
  7.3.1. Rheumatoid Arthritis
  7.3.2. Osteoarthritis
  7.3.3. Gout
  7.3.4. Psoriatic Arthritis
  7.3.5. Ankylosing Spondylitis
  7.3.6. Others
  7.4. Market Attractiveness, by Disease Indication
8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration
  8.1. Introduction and Definitions
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by Route of Administration, 2020-2034
  8.3.1. Parenteral Route
  8.3.2. Oral Route
  8.3.3. Topical
  8.4. Market Attractiveness, by Route of Administration
9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel
  9.1. Introduction and Definitions
  9.2. Key Findings/Developments
  9.3. Market Value Forecast, by Distribution Channel, 2020-2034
  9.3.1. Hospital Pharmacy
  9.3.2. Retail Pharmacy
  9.3.3. Online Pharmacy
  9.4. Market Attractiveness, by Distribution Channel
10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region
  10.1. Key Findings
  10.2. Market Value Forecast, by Region, 2020-2034
  10.2.1. North America
  10.2.2. Europe
  10.2.3. Asia Pacific
  10.2.4. Latin America
  10.2.5. Middle East & Africa
  10.3. Market Attractiveness, by Region
11. North America Rheumatology Therapeutics Market Analysis and Forecast
  11.1. Introduction
  11.1.1. Key Findings
  11.2. Market Value Forecast, by Drug Class, 2020-2034
  11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  11.2.3. Corticosteroids
  11.2.4. Uric Acid Drugs
  11.2.5. Others
  11.3. Market Attractiveness, by Drug Class
  11.4. Market Value Forecast, by Disease Indication, 2020-2034
  11.4.1. Rheumatoid Arthritis
  11.4.2. Osteoarthritis
  11.4.3. Gout
  11.4.4. Psoriatic Arthritis
  11.4.5. Ankylosing Spondylitis
  11.4.6. Others
  11.5. Market Attractiveness, by Disease Indication
  11.6. Market Value Forecast, by Route of Administration, 2020-2034
  11.6.1. Parenteral Route
  11.6.2. Oral Route
  11.6.3. Topical
  11.7. Market Attractiveness, by Route of Administration
  11.8. Market Value Forecast, by Distribution Channel, 2020-2034
  11.8.1. Hospital Pharmacy
  11.8.2. Retail Pharmacy
  11.8.3. Online Pharmacy
  11.9. Market Attractiveness, by Distribution Channel
  11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.10.1. U.S.
  11.10.2. Canada
  11.11. Market Attractiveness Analysis
  11.11.1. By Drug Class
  11.11.2. By Disease Indication
  11.11.3. By Route of Administration
  11.11.4. By Distribution Channel
  11.11.5. By Country
12. Europe Rheumatology Therapeutics Market Analysis and Forecast
  12.1. Introduction
  12.1.1. Key Findings
  12.2. Market Value Forecast, by Drug Class, 2020-2034
  12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  12.2.3. Corticosteroids
  12.2.4. Uric Acid Drugs
  12.2.5. Others
  12.3. Market Attractiveness, by Drug Class
  12.4. Market Value Forecast, by Disease Indication, 2020-2034
  12.4.1. Rheumatoid Arthritis
  12.4.2. Osteoarthritis
  12.4.3. Gout
  12.4.4. Psoriatic Arthritis
  12.4.5. Ankylosing Spondylitis
  12.4.6. Others
  12.5. Market Attractiveness, by Disease Indication
  12.6. Market Value Forecast, by Route of Administration, 2020-2034
  12.6.1. Parenteral Route
  12.6.2. Oral Route
  12.6.3. Topical
  12.7. Market Attractiveness, by Route of Administration
  12.8. Market Value Forecast, by Distribution Channel, 2020-2034
  12.8.1. Hospital Pharmacy
  12.8.2. Retail Pharmacy
  12.8.3. Online Pharmacy
  12.9. Market Attractiveness, by Distribution Channel
  12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.10.1. Germany
  12.10.2. U.K.
  12.10.3. France
  12.10.4. Italy
  12.10.5. Spain
  12.10.6. Rest of Europe
  12.11. Market Attractiveness Analysis
  12.11.1. By Drug Class
  12.11.2. By Disease Indication
  12.11.3. By Route of Administration
  12.11.4. By Distribution Channel
  12.11.5. By Country/Sub-region
13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast
  13.1. Introduction
  13.1.1. Key Findings
  13.2. Market Value Forecast, by Drug Class, 2020-2034
  13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  13.2.3. Corticosteroids
  13.2.4. Uric Acid Drugs
  13.2.5. Others
  13.3. Market Attractiveness, by Drug Class
  13.4. Market Value Forecast, by Disease Indication, 2020-2034
  13.4.1. Rheumatoid Arthritis
  13.4.2. Osteoarthritis
  13.4.3. Gout
  13.4.4. Psoriatic Arthritis
  13.4.5. Ankylosing Spondylitis
  13.4.6. Others
  13.5. Market Attractiveness, by Disease Indication
  13.6. Market Value Forecast, by Route of Administration, 2020-2034
  13.6.1. Parenteral Route
  13.6.2. Oral Route
  13.6.3. Topical
  13.7. Market Attractiveness, by Route of Administration
  13.8. Market Value Forecast, by Distribution Channel, 2020-2034
  13.8.1. Hospital Pharmacy
  13.8.2. Retail Pharmacy
  13.8.3. Online Pharmacy
  13.9. Market Attractiveness, by Distribution Channel
  13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.10.1. China
  13.10.2. Japan
  13.10.3. India
  13.10.4. Australia & New Zealand
  13.10.5. Rest of Asia Pacific
  13.11. Market Attractiveness Analysis
  13.11.1. By Drug Class
  13.11.2. By Disease Indication
  13.11.3. By Route of Administration
  13.11.4. By Distribution Channel
  13.11.5. By Country/Sub-region
14. Latin America Rheumatology Therapeutics Market Analysis and Forecast
  14.1. Introduction
  14.1.1. Key Findings
  14.2. Market Value Forecast, by Drug Class, 2020-2034
  14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  14.2.3. Corticosteroids
  14.2.4. Uric Acid Drugs
  14.2.5. Others
  14.3. Market Attractiveness, by Drug Class
  14.4. Market Value Forecast, by Disease Indication, 2020-2034
  14.4.1. Rheumatoid Arthritis
  14.4.2. Osteoarthritis
  14.4.3. Gout
  14.4.4. Psoriatic Arthritis
  14.4.5. Ankylosing Spondylitis
  14.4.6. Others
  14.5. Market Attractiveness, by Disease Indication
  14.6. Market Value Forecast, by Route of Administration, 2020-2034
  14.6.1. Parenteral Route
  14.6.2. Oral Route
  14.6.3. Topical
  14.7. Market Attractiveness, by Route of Administration
  14.8. Market Value Forecast, by Distribution Channel, 2020-2034
  14.8.1. Hospital Pharmacy
  14.8.2. Retail Pharmacy
  14.8.3. Online Pharmacy
  14.9. Market Attractiveness, by Distribution Channel
  14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  14.10.1. Brazil
  14.10.2. Mexico
  14.10.3. Rest of Latin America
  14.11. Market Attractiveness Analysis
  14.11.1. By Drug Class
  14.11.2. By Disease Indication
  14.11.3. By Route of Administration
  14.11.4. By Distribution Channel
  14.11.5. By Country/Sub-region
15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast
  15.1. Introduction
  15.1.1. Key Findings
  15.2. Market Value Forecast, by Drug Class, 2020-2034
  15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
  15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
  15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
  15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  15.2.3. Corticosteroids
  15.2.4. Uric Acid Drugs
  15.2.5. Others
  15.3. Market Attractiveness, by Drug Class
  15.4. Market Value Forecast, by Disease Indication, 2020-2034
  15.4.1. Rheumatoid Arthritis
  15.4.2. Osteoarthritis
  15.4.3. Gout
  15.4.4. Psoriatic Arthritis
  15.4.5. Ankylosing Spondylitis
  15.4.6. Others
  15.5. Market Attractiveness, by Disease Indication
  15.6. Market Value Forecast, by Route of Administration, 2020-2034
  15.6.1. Parenteral Route
  15.6.2. Oral Route
  15.6.3. Topical
  15.7. Market Attractiveness, by Route of Administration
  15.8. Market Value Forecast, by Distribution Channel, 2020-2034
  15.8.1. Hospital Pharmacy
  15.8.2. Retail Pharmacy
  15.8.3. Online Pharmacy
  15.9. Market Attractiveness, by Distribution Channel
  15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  15.10.1. GCC Countries
  15.10.2. South Africa
  15.10.3. Rest of Middle East & Africa
  15.11. Market Attractiveness Analysis
  15.11.1. By Drug Class
  15.11.2. By Disease Indication
  15.11.3. By Route of Administration
  15.11.4. By Distribution Channel
  15.11.5. By Country/Sub-region
16. Competition Landscape
  16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  16.2. Market Share Analysis, by Company (2023)
  16.3. Company Profiles
  16.3.1. F. Hoffmann-La Roche Ltd.
  16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.1.2. Product Portfolio
  16.3.1.3. Financial Overview
  16.3.1.4. SWOT Analysis
  16.3.1.5. Strategic Overview
  16.3.2. AbbVie, Inc.
  16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.2.2. Product Portfolio
  16.3.2.3. Financial Overview
  16.3.2.4. SWOT Analysis
  16.3.2.5. Strategic Overview
  16.3.3. Pfizer, Inc.
  16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.3.2. Product Portfolio
  16.3.3.3. Financial Overview
  16.3.3.4. SWOT Analysis
  16.3.3.5. Strategic Overview
  16.3.4. Takeda Pharmaceutical Company Limited
  16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.4.2. Product Portfolio
  16.3.4.3. Financial Overview
  16.3.4.4. SWOT Analysis
  16.3.4.5. Strategic Overview
  16.3.5. Amgen, Inc.
  16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.5.2. Product Portfolio
  16.3.5.3. Financial Overview
  16.3.5.4. SWOT Analysis
  16.3.5.5. Strategic Overview
  16.3.6. Genentech, Inc.
  16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.6.2. Product Portfolio
  16.3.6.3. Financial Overview
  16.3.6.4. SWOT Analysis
  16.3.6.5. Strategic Overview
  16.3.7. Novartis AG
  16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.7.2. Product Portfolio
  16.3.7.3. Financial Overview
  16.3.7.4. SWOT Analysis
  16.3.7.5. Strategic Overview
  16.3.8. Johnson & Johnson Innovative Medicine
  16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.8.2. Product Portfolio
  16.3.8.3. Financial Overview
  16.3.8.4. SWOT Analysis
  16.3.8.5. Strategic Overview
  16.3.9. Sanofi
  16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.9.2. Product Portfolio
  16.3.9.3. Financial Overview
  16.3.9.4. SWOT Analysis
  16.3.9.5. Strategic Overview
  16.3.10. Merck & Co., Inc.
  16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  16.3.10.2. Product Portfolio
  16.3.10.3. Financial Overview
  16.3.10.4. SWOT Analysis
  16.3.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings